Company in its Board Meeting has approved financial results for period ended 31st march, 2026
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 27 May 2026, 04:53 PM IST · BSE ID: 8680a093-9ea6-4596-a4d8-05483dccc88a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company declared its yearly financial performance, showing Rs. 408.91 Lakhs net profit for the year ending March 2026.
🤖 AI Summary
- Godavari Drugs Board approved audited financial results for Q4 and FY ended March 31, 2026.
- Net profit for the financial year ended March 31, 2026, was Rs. 408.91 Lakhs.
- Total Revenue from operations for FY26 reached Rs. 10661.32 Lakhs.
- M/s. S.K. Lahoti Associates appointed Internal Auditors and M/S. Bharathula & Associates as Cost Auditors for FY27.
- The 38th Annual General Meeting is scheduled for September 25, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue from operations (Year ended 31.03.2026)
10661.32 Lakhs
-6.74%
Net Profit for the period (Year ended 31.03.2026)
408.91 Lakhs
-6.64%
Basic Earnings per share (Year ended 31.03.2026)
5.43
-6.70%
Diluted Earnings per share (Year ended 31.03.2026)
5.36
-7.90%
🏢 How This Affects the Company
Net Profit for FY26 decreased to Rs. 408.91 Lakhs from Rs. 438.00 Lakhs in FY25. Revenue from operations also saw a decline from Rs. 11335.01 Lakhs in FY25 to Rs. 10580.81 Lakhs in FY26.
The appointment of new Internal and Cost Auditors for FY27 indicates an update in the company's financial audit and control mechanisms.
The declaration of an unmodified audit opinion for the financial year ended March 31, 2026, confirms no material misstatements in the financial reporting.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take immediate action based on this financial results filing; however, participation in the Annual General Meeting is encouraged.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with FY26 diluted EPS at Rs. 5.36, down from Rs. 5.82 in FY25. The preferential allotment in March 2026 increased paid-up equity share capital to 1012.74 Lakhs.
🔍
Management Signal
Management is maintaining compliance through timely financial disclosures and the appointment of independent auditors, alongside preparing for the annual shareholder meeting.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 financial results — check revenue and net profit trends.
Outcome of the 38th Annual General Meeting on September 25, 2026.
Any further announcements regarding new internal or cost audit findings.
LOW RISK
The company reported no outstanding defaults and received an unmodified audit opinion for FY26.
💡 Investor Takeaway
Godavari Drugs Ltd reported a Net Profit of Rs. 408.91 Lakhs for the financial year ended March 31, 2026, down 6.64% from Rs. 438.00 Lakhs in FY25. Revenue from operations also decreased to Rs. 10580.81 Lakhs from Rs. 11335.01 Lakhs over the same period, indicating a decline in annual performance.
⚖️ Strengths & Concerns
✅ Positives
- The statutory auditors, M/s. Ayyadevara & Co., issued an unmodified opinion on the audited financial results for FY26.
- Godavari Drugs reported no outstanding default on loans and debt securities during the quarter ended March 31, 2026.
⚠️ Concerns
- Net Profit for FY26 declined to Rs. 408.91 Lakhs compared to Rs. 438.00 Lakhs for FY25, a decrease of 6.64%.
- Total Revenue from operations for FY26 decreased to Rs. 10580.81 Lakhs from Rs. 11335.01 Lakhs in FY25, a 6.74% reduction.
❓ Frequently Asked Questions
What was Godavari Drugs Ltd's net profit for the financial year ended March 31, 2026?
Godavari Drugs Ltd reported a net profit of Rs. 408.91 Lakhs for the financial year ended March 31, 2026, compared to Rs. 438.00 Lakhs in the prior year.
What was the total revenue from operations for Godavari Drugs Ltd in FY26?
Total revenue from operations for Godavari Drugs Ltd was Rs. 10661.32 Lakhs for the financial year ended March 31, 2026, down from Rs. 11432.73 Lakhs in FY25.
Has Godavari Drugs Ltd appointed new auditors for FY27?
Yes, Godavari Drugs Ltd has appointed M/s. S.K. Lahoti Associates as Internal Auditors and M/S. Bharathula & Associates as Cost Auditors for the Financial Year 2026-27.
What is the diluted EPS for Godavari Drugs Ltd for the year ended March 31, 2026?
The diluted Earnings Per Share (EPS) for Godavari Drugs Ltd for the year ended March 31, 2026, is Rs. 5.36.
Questions based on this BSE filing only. For information purposes.